drugset / Trial / NCT00455598
Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to provide an initial assessment of the safety, tolerability and efficacy of ISIS 113715 in combination with sulfonylurea in type 2 diabetes subjects.
Timeline
- Start
- 2007-02
- Primary completion
- 2009-03
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ISIS 113715 | Antisense oligonucleotide | 100 mg | — |
| Comparator | ISIS 113715 | Antisense oligonucleotide | 200 mg | — |